A Single-dose, Open-label, Parallel-group Study to Assess the Pharmacokinetics of BAF312 in Subjects With Renal Impairment Compared to Subjects With Normal Renal Function

Trial Profile

A Single-dose, Open-label, Parallel-group Study to Assess the Pharmacokinetics of BAF312 in Subjects With Renal Impairment Compared to Subjects With Normal Renal Function

Completed
Phase of Trial: Phase I

Latest Information Update: 14 Nov 2016

At a glance

  • Drugs Siponimod (Primary)
  • Indications Dermatomyositis; Multiple sclerosis; Polymyositis; Renal impairment
  • Focus Pharmacokinetics
  • Sponsors Novartis
  • Most Recent Events

    • 14 Nov 2016 Results published in the International Journal of Clinical Pharmacology and Therapeutics
    • 03 Jun 2015 Status changed from recruiting to completed as per ClinicalTrials.gov record.
    • 07 Jan 2015 Planned End Date changed from 1 Jan 2015 to 1 Jul 2015 according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top